Telix Pharmaceuticals is trading at $11.19, up +4.14%, with healthcare-sector strength the clearest available context.
- Healthcare is up 2.12%, as investors rotate toward healthcare stocks.
- Telix announced an Ekalia collaboration on October 19, 2026, to develop U.S. astatine-211 production; available reporting does not confirm it caused the move.
- The ITM acquisition was announced in September, not a new October 20 catalyst; no confirmed company-specific trigger or volume data was found.